Michael Frazis gives an update and answers questions.
0:26 – Introduction
1:10 – Performance update
1:58 – Comments on the NASDAQ100’s strong rally
2:46 – The performance of small-mid cap companies
3:38 – An analyse of where our returns have come from over the years
4:20 – Our past investment in bluebird bio
5:39 – Our IPO/pre-IPO investments in the life sciences
6:57 – We funded a PhD fellowship on research into Dystonia
8:45 – True customer love and explosive growth
9:14 – Our take on ESG and the rising coal prices
10:40 – The effects of currency fluctuations on a fund’s performance
12:23 – Drivers in the value of the AUD
13:36 – Comments on Opendoor and the three industries that are resistant to ecommerce
16:25 – Comments on Upstart
18:42 –Thoughts on the decline in digital health companies
20:03 – Question #1: What do you think of PointsBet?
21:31 – Question #2: Do we still hold Guardent and Dermtech?
23:30 – Question #3: The contribution of the life science companies to the fund’s performance
26:08 – Question #4: Are you planning on taking advantage of the current dip in the market?
26:23 – Question #5: What are the risk management strategies when if the market turns?
28:51 – Question #6: Customer love in the life sciences
29:09 – Question #7: How has the recent move back into China-tech progressed?
30:12 – Question #8: What do you think of developer tools ecosystem DevOps?
30:51 – Question #9: What is an odd stock that looks good at the moment? (Camplify and Cettire)
31:35 – Question #10: What are your thoughts on Megaport?
31:50 – Question #11: What are your thoughts on cloud in general? (Snowflake)
32:58 – Question #12: Do you see the fund’s China positions as trading or long-term holds? (Pinduoduo)
36:25 – Question #13: Would eye-wear replace mobiles?
37:20 – Question #14: What are your thoughts on the recent Canva valuation?
40:18 – Question #15: What are your thoughts on Fiverr?
